Skip to main content

Advertisement

SpringerLink
Log in

The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

High levels of indoleamine 2,3-dioxygenase (IDO) are involved in tumour escape mechanisms. The aim of this study is the evaluation of l-kynurenine of plasma as marker of diagnostic and prognostic in patients with colorectal cancer. The study included 78 patients with colorectal cancer, of whom 15 % were in stage I/II, 30 % in stage III, and 55 % in stage IV, and was compared with a control group of 70 healthy subjects. The receiver operating characteristic (ROC) curve analysis showed an area under the curve of 0.917, with a specificity of 100 % and with a sensitivity to detect cancer of the colon of 85.2 %, taking 1.83 μM as a cut-off point. The overall survival analysis also indicated that patients with low levels of l-kynurenine in plasma increased survival rate after 45 months of follow-up (P = 0.032). These results show that the plasma levels of l-kynurenine could be a good biomarker to differentiate individuals with colorectal cancer from healthy individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Karsa LV, Lignini TA, Patnick J, Lambert R, Sauvaget C (2010) The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol 24:381–396

    Article  PubMed  CAS  Google Scholar 

  2. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (2003) Clinical utility of biochemical markers in colorectal cancer: European group on tumor markers (EGTM) guidelines. Eur J Cancer 39:718–727

    Article  PubMed  CAS  Google Scholar 

  3. Carpelan-Holmstrom M, Louhimo J, Stenman UA, Alfthan H, Jarvinen H, Haglund C (2004) Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 66:296–302

    Article  PubMed  CAS  Google Scholar 

  4. Basbug M, Arikanoglu Z, Bulbuller N, Cetinkaya Z, Aygen E, Akbulut S, Satici O (2011) Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. Hepatogastroenterology 58:400–405

    PubMed  CAS  Google Scholar 

  5. Tjalsma H (2010) Identification of biomarkers for colorectal cancer through proteomics-based approaches. Expert Rev Proteomics 7:879–895

    Article  PubMed  CAS  Google Scholar 

  6. Babel I, Barderas R, Díaz-Uriarte R, Martínez-Torrecuadrada JL, Sánchez-Carbayo M, Casal JI (2009) Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 8:2382–2395

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  7. Silk AW, Schoen RE, Potter DM, Finn OJ (2009) Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol 47:52–56

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  8. Ran Y, Hu H, Zhou Z, Yu L, Sun L, Pan J, Liu J, Yang Z (2008) Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res 14:2696–2700

    Article  PubMed  CAS  Google Scholar 

  9. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O (2007) Tumor markers in colorectal cancer: European group on tumor markers (EGTM) guidelines for clinical use. Eur J Cancer 43:1348–1360

    Article  PubMed  CAS  Google Scholar 

  10. Ninomiya S, Hara T, Tsurumi H, Hoshi M, Kanemura N, Goto N, Kasahara S, Shimizu M, Ito H, Saito K, Hirose Y, Yamada T, Takahashi T, Seishima M, Takami T, Moriwaki H (2011) Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 90:409–416

    Article  PubMed  CAS  Google Scholar 

  11. Nonaka H, Saga Y, Fujiwara H, Akimoto H, Yamada A, Kagawa S, Takei Y, Machida S, Takikawa O, Suzuki M (2011) Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killer cell function and angiogenesis promotion. Int J Oncol 38:113–120

    PubMed  CAS  Google Scholar 

  12. Inaba T, Ino K, Kajiyama H, Shibata K, Yamamoto E, Kondo S, Umezu T, Nawa A, Takikawa O, Kikkawa F (2010) Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 117:423–428

    Article  PubMed  CAS  Google Scholar 

  13. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F (2008) Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14:2310–2317

    Article  PubMed  CAS  Google Scholar 

  14. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, McCormick D, Jager MJ, Cree IA (2007) Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 960:1879–1887

    Article  CAS  Google Scholar 

  15. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Göbel G, Margreiter R, Königsrainer A, Fuchs D, Amberger A (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12:1144–1151

    Article  PubMed  CAS  Google Scholar 

  16. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274

    Article  PubMed  CAS  Google Scholar 

  17. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147–1154

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Gao YF, Peng RQ, Li J, Ding Y, Zhang X, Wu XJ, Pan ZZ, Wan DS, Zeng YX, Zhang XS (2009) The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med 7:71

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  19. Cavia-Saiz M, Muñiz P, De Santiago R, Herreros-Villanueva M, Garcia-Giron C, Lopéz AS, Coma-del Corral MJ (2012) Changes in the levels of thioredoxin and indoleamine-2-3 dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy. Biochem Cell Biol 90:173–178

    Article  PubMed  CAS  Google Scholar 

  20. Alegre E, López AS, González A (2005) Tryptophan metabolites interfere with the Ehrlich reaction used for the measurement of kynurenine. Anal Biochem 339:188–189

    Article  PubMed  CAS  Google Scholar 

  21. Singer K, Gottfried E, Kreutz M, Mackensen A (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother 60:425–431

    Article  PubMed  CAS  Google Scholar 

  22. Laimer K, Troester B, Kloss F, Schafer G, Obrist P, Perathoner A, Laimer J, Brandacher G, Rasse M, Margreiter R, Amberger A (2011) Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 47:352–357

    Article  PubMed  CAS  Google Scholar 

  23. Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC (2008) Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134:1247–1253

    Article  PubMed  CAS  Google Scholar 

  24. Johnson BA, Baban B, Mellor AL (2009) Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 1:645–661

    PubMed Central  PubMed  CAS  Google Scholar 

  25. Ciorba MA (2013) Indoleamine 2,3 dioxygenase in intestinal disease. Curr Opin Gastroenterol 29:146–152

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  26. Mead R, Duku M, Bhandari P, Cree IA (2011) Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer 105:239–245

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  27. Zhu CB, Wang CX, Zhang X, Zhang J, Li W (2011) Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int J Cancer 128:617–622

    Article  PubMed  CAS  Google Scholar 

  28. Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, Kanemura N, Kasahara S, Ito H, Takemura M, Saito K, Seishima M, Takami T, Moriwaki H (2010) Serum concentration of l-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 84:304–309

    Article  PubMed  CAS  Google Scholar 

  29. Seval Kul (2010) The use of survival analysis for clinical pathways. Int J Care Pathw 14:23–26

    Article  Google Scholar 

Download references

Acknowledgments

Authors wish to thank to the Banca Civica for their financial support through of the Research Projects of 2010. This work was supported by a grant FIS CA07/00292 from Instituto de Salud Carlos III.

Conflict of interest

The authors have no conflict of interest to report.

Author information

Authors and Affiliations

  1. Research Unit, University Hospital of Burgos, Burgos, Spain

    M. Cavia-Saiz & M. J. Coma-del Corral

  2. Biochemistry and Molecular Biology Area, University of Burgos, Burgos, Spain

    P. Muñiz Rodríguez

  3. Oncology Unit, University Hospital of Burgos, Burgos, Spain

    B. Llorente Ayala

  4. Oncology Service, University Hospital of Burgos, Burgos, Spain

    M. García-González & C. García Girón

Authors
  1. M. Cavia-Saiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Muñiz Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Llorente Ayala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. García-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. J. Coma-del Corral
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. García Girón
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Cavia-Saiz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cavia-Saiz, M., Muñiz Rodríguez, P., Llorente Ayala, B. et al. The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer. Mol Biol Rep 41, 2275–2279 (2014). https://doi.org/10.1007/s11033-014-3080-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3080-2

Keywords

Search

Navigation